In:
European Journal of Heart Failure, Wiley, Vol. 16, No. 1 ( 2014-01), p. 76-85
Abstract:
Heart rate not only predicts outcome but may also be a therapeutic target in patients with chronic heart failure. Several classes of pharmacological agents can be used to modulate heart rate, including beta‐blockers, ivabradine, digoxin, amiodarone, and verapamil. Choice of agent will depend on heart rhythm, co‐morbidities, and disease phenotype. Beneficial and harmful interactions may also exist. The aim of this paper is to summarize the current body of knowledge regarding the relevance of heart rate as a prognostic factor (risk marker) and particularly as a therapeutic target (risk factor) in patients with chronic heart failure, with a special focus on ivabradine, a novel agent that is currently the only available purely bradycardic agent.
Type of Medium:
Online Resource
ISSN:
1388-9842
,
1879-0844
DOI:
10.1093/eurjhf/hft129
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
1500332-2
Permalink